Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (methotrexate or bexarotene): The phase 3 alcanza study Meeting Abstract
| Authors: | Kim, Y. H.; Whittaker, S.; Horwitz, S. M.; Duvic, M.; Dummer, R.; Scarisbrick, J. J.; Quaglino, P.; Zinzani, P. L.; Wolter, P.; Wang, Y.; Palanca-Wessels, M. C.; Zagadailov, E.; Trepicchio, W. L.; Liu, Y.; Little, M.; Prince, H. M. |
| Abstract Title: | Brentuximab vedotin demonstrates significantly superior clinical outcomes in patients with CD30-expressing cutaneous T cell lymphoma versus physician's choice (methotrexate or bexarotene): The phase 3 alcanza study |
| Meeting Title: | 58th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 128 |
| Issue: | 22 |
| Meeting Dates: | 2016 Dec 3-6 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2016-12-02 |
| Language: | English |
| ACCESSION: | WOS:000394446803146 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V128.22.182.182 |
| Notes: | Meeting Abstract: 182 -- Source: Wos |
